Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00235053 · ClinicalTrials.gov registry record · Phase 4
Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID
A Phase 4 study, sponsored by Allergy & Asthma Medical Group & Research Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 13
- Enrollment target
NCT00235053: Completed Phase 4 study, sponsored by Allergy & Asthma Medical Group & Research Center.
NCT00235053 is a Phase 4 study that has completed, run by Allergy & Asthma Medical Group & Research Center. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00235053, a Phase 4 study, has completed, sponsored by Allergy & Asthma Medical Group & Research Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 13 participants
- Enrollment target
Study Summary
This Pilot study is designed to explore the rate of local side effects of fluticasone as delivered by Advair and to determine the best outcome measure to assess these effects. This study is the initial step, and will be followed by a larger scale study.
Interventions
- DRUG fluticasone/salmeterol DISKUS 250/50
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2005-08 |
| Est. Completion | 2005-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00235053
The ClinicalTrials.gov registry entry for NCT00235053 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergy & Asthma Medical Group & Research Center, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which fluticasone/salmeterol DISKUS 250/50 is the first listed.
NCT00235053 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00235053 about?
NCT00235053 is a clinical study titled "Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID". This Pilot study is designed to explore the rate of local side effects of fluticasone as delivered by Advair and to determine the best outcome measure to assess these effects. This study is the initial step, and will be followed by a larger scale study.
What is the current status of trial NCT00235053?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 13 participants. The study started on 2005-08. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00235053?
The interventions under investigation include: fluticasone/salmeterol DISKUS 250/50 (DRUG).
Who is sponsoring clinical trial NCT00235053?
This trial is sponsored by Allergy & Asthma Medical Group & Research Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.